Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae. It is also used to protect adults and the elderly against invasive disease and pneumonia caused by S.

If Prevnar 13 is given as part of a routine infant immunization program, a 3-dose (2+1) schedule may be considered. The first dose may be given from the age of 2 months, with a second dose 2 months later, and a third (booster) dose is recommended between 11-12 months of age.

Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers, children and adults.

One pneumonia vaccine (Prevnar 13) has an unknown immunity duration, while the other (Pneumovax 23) lasts from five to 10 years. Pneumonia is an infection of the lungs that causes cough, fever, and trouble breathing.

Children 6 - 17 years and adults: One single dose. Special populations: Individuals considered to be at a higher risk of pneumococcal infection may receive at least one dose of Prevenar 13. Your doctor will advise the appropriate vaccination schedule.

PCV vaccines are recommended to be given first because this sequence provides the best immune response to both PCV and PPSV23 vaccines.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age. a Dose 1 may be given as early as 6 weeks of age. b The recommended dosing interval is 4 to 8 weeks.

One dose of PCV13 is recommended for adults: 65 years or older who have not previously received PCV13. 19 years or older with certain medical conditions and who have not previously received PCV13.

If you get pneumococcal vaccines for the first time at 65 or older, you will need two shots, one year apart. If you've had only one pneumococcal vaccine in your lifetime, you may now need an additional shot. If you had the pneumococcal vaccine before you were 65, you may now need one or two additional shots.

Yes. If immunization with Prevnar 13 is being considered, the National Advisory Committee on Immunization (NACI) recommends administration of Prevnar 13 at least one year after any previous dose of PNEU-P-23 in immunocompetent adults aged 65 years and older.

The pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23) protect against pneumococcal infections. The bacteria that cause these infections spread through person-to-person contact. They can lead to serious infections like pneumonia, blood infections, and bacterial meningitis.

– Administer 1 dose of PCV13 at least 1 year after the most recent pneumococcal vaccine dose. – Administer a second dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the previous dose of PPSV23 (note: a second dose is not indicated for those with CSF leaks or cochlear implants).